Saxenda in Obesity Services (STRIVE Study)

NCT03036800 on ClinicalTrials.gov · last registry update 2024-08-13

An unusually large phase 4: 392 participants, more than double the 75 typical for the stage. The sponsor logged completion for 28 February 2021. Primary outcome, as filed: Weight Loss of ≥15% From Baseline (Complete Cases). liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Leicester
Sponsor type: Other
Enrollment: 392
Started: 2017-11-28
Primary completion: 2021-02-28 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Weight Loss of ≥15% From Baseline (Complete Cases)

Conditions studied

Obesity · Weight Loss · Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.